published meta-analysis   sensitivity analysis   studies

Immunostimulants drugs in COVID 19 all comers - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsLIFESAVER, 2021 2.00 [0.16; 24.66] 2.00[0.16; 24.66]LIFESAVER, 202110%12NAnot evaluable deathsdetailed resultsLIFESAVER, 2021 2.00 [0.16; 24.66] 2.00[0.16; 24.66]LIFESAVER, 202110%12NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:22 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 94 - treatments: 597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567 - roots T: 290